Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FDA-approved fulvestrant-induced CAR phase separation enables precise control of CAR T antitumor function.

Cell stem cell·2026

Same author

Real time prediction of instantaneous wave-free ratio based on lumped parameter and neural network models.

Computer methods and programs in biomedicine·2026

Same author

Identification of highly expressed genes and efficient core promoters specific to buffalo skeletal muscles.

Archives animal breeding·2026

Same author

RNA sequencing reveals lncRNAs that specifically regulate unsaturated fatty acid generation in buffaloes.

Archives animal breeding·2026

Same author

Sex differences in resting-state hypothalamic connectivity and its relationship with negative emotion and behavior measures in young adults.

Brain structure & function·2026

Same author

Non-invasive Computational Techniques for Diagnosing Myocardial Ischemia: Challenges and Future of FFR<sub>CT</sub>/iFR<sub>CT</sub>.

Annals of biomedical engineering·2026

Search research articles

Related Experiment Video

Updated: Sep 4, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

B7-H3-targeted CAR-T cell therapy for solid tumors.

Guangfei Li¹, Haopeng Wang², Haitao Wu¹

¹ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.

International Reviews of Immunology

|July 20, 2022

Summary

Chimeric antigen receptor (CAR) T-cell and CAR-NK cell therapies targeting B7-H3 show initial safety but limited efficacy in solid tumors. Strategies like local delivery and combination therapies may enhance treatment effectiveness.

Keywords:

B7-H3 CAR-T solid tumors

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Sep 4, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Immunology
Oncology

Background:

B7-H3 is overexpressed in various solid tumors, making it a promising target for immunotherapy.
Restricted expression in normal tissues enhances B7-H3's potential as a specific therapeutic target.

Approach:

This review focuses on the structural design of chimeric antigen receptors (CARs) targeting B7-H3.
It discusses B7-H3 expression, receptor function, and monoclonal antibody therapies.
Summarizes preclinical and clinical data on B7-H3-targeted CAR-T and CAR-NK cell therapies.

Key Points:

B7-H3-targeted CAR-based cell therapies have demonstrated safety in early trials.
Initial clinical trials indicate limited efficacy for B7-H3-targeted CAR cell therapies in solid tumors.
Current research explores enhancing CAR T-cell persistence and combining therapies.

Conclusions:

B7-H3 is a viable immunotherapeutic target for solid tumors.
Improving CAR T-cell therapy efficacy requires strategies such as local delivery and combination treatments.
Further research into CAR-T and CAR-NK cell modifications is crucial for advancing B7-H3-targeted cancer treatments.